Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

gilead sciences inc. - GILD

GILD

Close Chg Chg %
87.75 0.88 1.00%

Pre-Market

88.63

+0.88 (1.00%)

Volume: 4.78M

Last Updated:

Nov 20, 2024, 4:00 PM EDT

Trade Now

Company Overview: gilead sciences inc. - GILD

GILD Key Data

Open

$88.34

 Day Range

87.77 - 89.07

52 Week Range

62.07 - 98.90

 Market Cap

$109.36B

Shares Outstanding

1.25B

 Public Float

1.25B

Beta

0.19

 Rev. Per Employee

N/A

P/E Ratio

989.29

 EPS

$0.10

Yield

348.72%

 Dividend

$0.77

EX-DIVIDEND DATE

Dec 13, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

7.33M

  

GILD Performance

1 Week
 
 0.26%
 
1 Month
 
 -0.42%
 
3 Months
 
 15.52%
 
1 Year
 
 17.58%
 
5 Years
 
 35.81%
 

GILD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 32
Full Ratings ➔

About gilead sciences inc. - GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

GILD At a Glance

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404
Phone 1-650-574-3000 Revenue 27.06B
Industry Biotechnology Net Income 5.66B
Sector Health Technology Employees 18,000
Fiscal Year-end 12 / 2024
View SEC Filings

GILD Valuation

P/E Current 989.29
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 17.989
Price to Sales Ratio 3.766
Price to Book Ratio 4.421
Price to Cash Flow Ratio 12.729
Enterprise Value to EBITDA 9.579
Enterprise Value to Sales 4.403
Total Debt to Enterprise Value 0.215

GILD Efficiency

Revenue/Employee 1,503,222.222
Income Per Employee 314,666.667
Receivables Turnover 5.806
Total Asset Turnover 0.432

GILD Liquidity

Current Ratio 1.426
Quick Ratio 1.268
Cash Ratio 0.74

GILD Profitability

Gross Margin 77.755
Operating Margin 36.012
Pretax Margin 25.349
Net Margin 20.933
Return on Assets 9.041
Return on Equity 25.703
Return on Total Capital 11.681
Return on Invested Capital 12.481

GILD Capital Structure

Total Debt to Total Equity 112.372
Total Debt to Total Capital 52.913
Total Debt to Total Assets 41.301
Long-Term Debt to Equity 103.95
Long-Term Debt to Total Capital 48.947
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Gilead Sciences Inc. - GILD

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
24.64B 27.37B 27.09B 27.06B
Sales Growth
+10.39% +11.08% -1.05% -0.10%
Cost of Goods Sold (COGS) incl D&A
4.51B 6.60B 5.66B 6.02B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.48B 2.05B 2.10B 2.69B
Depreciation
288.00M 329.00M 323.00M 354.00M
Amortization of Intangibles
1.19B 1.72B 1.78B 2.34B
COGS Growth
-3.55% +46.40% -14.30% +6.40%
Gross Income
20.13B 20.77B 21.43B 21.04B
Gross Income Growth
+14.09% +3.17% +3.16% -1.82%
Gross Profit Margin
+81.70% +75.88% +79.11% +77.76%
2020 2021 2022 2023 5-year trend
SG&A Expense
9.69B 10.57B 10.67B 11.29B
Research & Development
4.86B 5.36B 5.00B 5.76B
Other SG&A
4.83B 5.21B 5.67B 5.54B
SGA Growth
-23.63% +9.09% +0.96% +5.85%
Other Operating Expense
- - - -
-
Unusual Expense
2.94B 1.52B 4.21B 2.31B
EBIT after Unusual Expense
7.50B 8.68B 6.54B 7.44B
Non Operating Income/Expense
(4.85B) 600.00M 205.00M 366.00M
Non-Operating Interest Income
- - - 376.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
984.00M 1.00B 935.00M 944.00M
Interest Expense Growth
-1.11% +1.73% -6.59% +0.96%
Gross Interest Expense
984.00M 1.00B 935.00M 944.00M
Interest Capitalized
- - - -
-
Pretax Income
1.67B 8.28B 5.81B 6.86B
Pretax Income Growth
-67.66% +395.99% -29.77% +17.97%
Pretax Margin
+6.77% +30.24% +21.47% +25.35%
Income Tax
1.58B 2.08B 1.25B 1.25B
Income Tax - Current - Domestic
1.65B 2.00B 2.57B 1.86B
Income Tax - Current - Foreign
155.00M 185.00M 232.00M 381.00M
Income Tax - Deferred - Domestic
(261.00M) (65.00M) (1.66B) (956.00M)
Income Tax - Deferred - Foreign
38.00M (47.00M) 101.00M (39.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
89.00M 6.20B 4.57B 5.61B
Minority Interest Expense
(34.00M) (24.00M) (26.00M) (52.00M)
Net Income
123.00M 6.22B 4.59B 5.66B
Net Income Growth
-97.72% +4,960.98% -26.23% +23.34%
Net Margin Growth
+0.50% +22.74% +16.95% +20.93%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
123.00M 6.22B 4.59B 5.66B
Preferred Dividends
- - - -
-
Net Income Available to Common
123.00M 6.22B 4.59B 5.67B
EPS (Basic)
0.0979 4.9562 3.659 4.5393
EPS (Basic) Growth
-97.69% +4,962.51% -26.17% +24.06%
Basic Shares Outstanding
1.26B 1.26B 1.25B 1.25B
EPS (Diluted)
0.0974 4.9326 3.6387 4.5032
EPS (Diluted) Growth
-97.69% +4,964.27% -26.23% +23.76%
Diluted Shares Outstanding
1.26B 1.26B 1.26B 1.26B
EBITDA
11.92B 12.25B 12.86B 12.44B
EBITDA Growth
+87.37% +2.74% +4.97% -3.29%
EBITDA Margin
+48.39% +44.76% +47.48% +45.96%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 98.50
Number of Ratings 32 Current Quarters Estimate 1.716
FY Report Date 12 / 2024 Current Year's Estimate 4.371
Last Quarter’s Earnings 2.02 Median PE on CY Estimate N/A
Year Ago Earnings 6.72 Next Fiscal Year Estimate 7.493
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 24 8 27 28
Mean Estimate 1.72 1.75 4.37 7.49
High Estimates 2.16 1.92 4.89 8.32
Low Estimate 1.09 1.60 3.66 6.38
Coefficient of Variance 11.71 7.06 5.53 5.61

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 14 12
OVERWEIGHT 4 5 3
HOLD 13 13 14
UNDERWEIGHT 0 0 0
SELL 0 0 1
MEAN Overweight Overweight Overweight

Insider Actions for Gilead Sciences Inc. - GILD

Date Name Shares Transaction Value
Nov 8, 2024 Merdad V. Parsey Chief Medical Officer 125,189 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $57.92 per share 7,250,946.88
Nov 8, 2024 Merdad V. Parsey Chief Medical Officer 104,599 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $91.5 per share 9,570,808.50
Nov 8, 2024 Merdad V. Parsey Chief Medical Officer 99,599 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $91.5 per share 9,113,308.50
Nov 8, 2024 Merdad V. Parsey Chief Medical Officer 121,670 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 8, 2024 Johanna Mercier Chief Commercial Officer 73,127 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $91.28 per share 6,675,032.56
Jun 12, 2024 Deborah H. Telman EVP, Corporate Affairs & GC 38,930 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Daniel P. O'Day Chairman & CEO; Director 125,567 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Daniel P. O'Day Chairman & CEO; Director 490,449 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $65.25 per share 32,001,797.25
Jun 12, 2024 Daniel P. O'Day Chairman & CEO; Director 495,142 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Deborah H. Telman EVP, Corporate Affairs & GC 14,752 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Johanna Mercier Chief Commercial Officer 120,469 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $65.25 per share 7,860,602.25
Jun 12, 2024 Johanna Mercier Chief Commercial Officer 43,697 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Andrew D. Dickinson Chief Financial Officer 138,622 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Deborah H. Telman EVP, Corporate Affairs & GC 14,548 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $65.25 per share 949,257.00
Jun 12, 2024 Sandra K. Patterson SVP, Controllership 33,533 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Sandra K. Patterson SVP, Controllership 17,762 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Sandra K. Patterson SVP, Controllership 33,278 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $65.25 per share 2,171,389.50
Jun 12, 2024 Andrew D. Dickinson Chief Financial Officer 42,768 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Andrew D. Dickinson Chief Financial Officer 136,960 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $65.25 per share 8,936,640.00
May 10, 2024 Harish M. Manwani Director 12,873 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $64.92 per share 835,715.16

Gilead Sciences Inc. in the News

Healthcare

Inside the race for a COVID-19 treatment pill

Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.

Markets

COVID-19 vaccine start-up files for IPO

The biotech startup behind the COVID-fox19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S. regulators for a public share offering. Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus.